Document is current
Any future updates will be listed below
-
Authors
Lobaina, Yadira
Musacchio, Alexis
Ai, Panchao
Chen, Rong
Suzarte, Edith
Chinea, Glay
Zhang, Miaohong
Zhou, Zhiqiang
Lan, Yaqin
Silva, Ricardo
Guillén, Gerardo
Yang, Ke
Li, Wen
Perera, Yasser
Hermida, Lisset
-
Funding
Funding for this research was provided by:
PNCT CITMA, Cuba
Hunan Provincial Base for Scientific and Technological Innovation Cooperation (2019CB1012)
The Science and Technology Innovation Program of Hunan Province (2020RC5035)
Ministry of Science and Technology of the People's Republic of China (2021YFE0192200)
Hunan Provincial Innovative Construction Program (2020WK2031)
- License Information
-
More Information
Article History
Received: 15 July 2024
Accepted: 18 November 2024
First Online: 29 November 2024
Declarations
:
: The human sera from COVID-19 convalescent and negative individuals were collected at the Eighth- and Ninth-People’s Hospital of Dongguan city (Guangdong Province, China). The study protocol was approved by the Institutional Ethics Committee from both hospitals and was carried out in accordance with the principles of Helsinki declaration. Informed consent was obtained from all donors.
: The studies in mice were conducted at Beijing Vital River Laboratory Animal Technology Co., Ltd, and Hunan Prima Drug Research Center Co., Ltd. Both animal facilities complied with the national standard of the People's Republic of China GB14925-2010 and the institutional guidelines. Each experimental protocol was subjected to analysis and approval by the Institutional Ethics Committee (Protocols: PANCOV04 approved on 12.04.2022, and HNSE2023(3)012 approved on 20.02.2023). In all the studies inhaled isoflurane, at regular dose or overdose, was employed as anesthesia or euthanasia method, respectively.
: Y. Lobaina, A.M., P.A., R.C., E.S., Y. Lan, G.C., R.S., G.G, K.Y, Y.P., L.H., are authors of a patent (recently presented in China) related to the content of the manuscript.
